RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2007; 132(19): 1039-1042
DOI: 10.1055/s-2007-979378
DOI: 10.1055/s-2007-979378
Aktuelle Diagnostik & Therapie | Review article
Diabetologie, Nephrologie© Georg Thieme Verlag KG Stuttgart · New York
Diabetische Nephropathie
Diabetic nephropathyWeitere Informationen
Publikationsverlauf
eingereicht: 27.2.2007
akzeptiert: 26.4.2007
Publikationsdatum:
03. Mai 2007 (online)

Schlüsselwörter
Diabetische Nephropathie - Kardiovaskuläres Risiko - Nierenersatztherapie - Multifaktorieller Ansatz - RAAS-Hemmung - Insulintherapie
Key words
diabetic nephropathy - kidney replacement therapy - cardiovascular risk - multifactorial intervention - RAAS-Inhibition - insulin therapy
Literatur
- 1
Basi S, Lewis J B.
Microalbuminuria as a target to improve cardiovascular and renal outcomes.
Am J Kidney Dis.
2006;
47
927-946
MissingFormLabel
- 2
Casas J P, Chua W, Loukogeorgakis S, Vallance P. et al .
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs
on renal outcomes.
Lancet.
2005;
366
2026-2033
MissingFormLabel
- 3
Collins R, Armitage J, Parish S. et al. Heart Protection Study Collaborative Group .
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people
with diabetes: a randomised placebo-controlled trial.
Lancet.
2003;
361
2005-2016
MissingFormLabel
- 4
Gaede P, Vedel P, Larsen N. et al .
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
N Engl J Med.
2003;
348
383-393
MissingFormLabel
- 5
Haller H, Viberti G C, Mimran A. et al .
Preventing microalbuminuria in patients with diabetes: rationale and design of the
Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
J Hypertens.
2006;
24
403
MissingFormLabel
- 6
MacKinnon M, Shurraw S, Akbari A. et al .
Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric
renal disease: a systematic review of the efficacy and safety data.
Am J Kidney Dis.
2006;
48
8-20
MissingFormLabel
- 7
Mogensen C E.
Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British
trial shows clear effects of treatment, especially blood pressure reduction.
BMJ.
1998;
317
693-694
MissingFormLabel
- 8
National Kidney Foundation .
K/DOQI clinical practice guidelines for chronic kidney disease. evaluation, classification
stratification.
Am J Kidney Dis.
2002;
(2 Suppl 1)
39
S1-266
MissingFormLabel
- 9
Parving H H, Lehnert H, Brochner-Mortensen J. et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group .
The effect of irbesartan on the development of diabetic nephropathy in patients with
type 2 diabetes.
N Engl J Med.
2001;
345
870-878
MissingFormLabel
- 10
Praxis Leitlinien der Deutschen Diabetes-Gesellschaft (DDG) .
Diabetische Nephropathie.
Diabetes und Stoffwechsel.
2002;
(Suppl 2)
17-19
MissingFormLabel
- 11
Rachmani R, Levi Z, Lidar M. et al .
Considerations about the threshold value of microalbuminuria in patients with diabetes
mellitus: lessons from an 8-year follow-up study of 599 patients.
Diabetes Res Clin Pract.
2000;
49
187-194
MissingFormLabel
- 12
Ritz E, Dikow R.
Hypertension and antihypertensive treatment of diabetic nephropathy.
Nat Clin Pract Nephrol.
2006;
2
562-567
MissingFormLabel
- 13
Ritz E, Orth S R.
Nephropathy in patients with type 2 diabetes mellitus (Review: No abstract available).
N Engl J Med.
1999;
341
1127-1133
MissingFormLabel
- 14
Ritz E, Schwenger V.
Lifestyle modification and progressive renal failure.
Nephrology (Carlton).
2005;
10
387-392
MissingFormLabel
- 15
Rossing P, Parving H H, de Zeeuw D.
Renoprotection by blocking the RAAS in diabetic nephropathy - fact or fiction?.
Nephrol Dial Transplant.
2006;
21
2354-2357
MissingFormLabel
- 16
Skrivarhaug T, Bangstad H J, Stene L C, Sandvik L, Hanssen K F, Joner G.
Low risk of overt nephropathy after 24 yr of childhood-onset type 1 diabetes mellitus
(T1DM) in Norway.
Pediatr Diabetes.
2006;
7
239-246
MissingFormLabel
- 17
The Diabetes Control and Complications Trial .
Retinopathy and Nephropathy in patients with type 1 diabetes four years after a trial
of intensive therapy.
N Engl J Med.
2000;
342
381-389
MissingFormLabel
- 18
Toeller M, Buyken A, Heitkamp G. et al .
Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications
Study.
Diabetologia.
1997;
40
1219-1226
MissingFormLabel
- 19
UK Prospective Diabetes Study (UKPDS) Group .
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet.
1998;
352
837
MissingFormLabel
- 20
Wanner C, Krane V, Marz W. et al. Deutsche Diabetes-Dialyse-Studie (4D) Study Group .
Randomized controlled trial on the efficacy and safety of atorvastatin in patients
with type 2 diabetes on hemodialysis (4D study).
Kidney Blood Press Res.
2004;
27
259-266
MissingFormLabel
Dr. Michael Morcos
Innere Medizin 1, Medizinische Universitätsklinik
INF 410
69120 Heidelberg
Telefon: 06221-568614
Fax: 06221-566848
eMail: Michael.Morcos@med.uni-heidelberg.de